Sun Pharmaceutical Industries had received approval from US health regulator to market generic Clarinex tablets and Tiazac capsules, used in treating nasal allergies and hypertension, respectively, in the US market.
The firm has received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to market a generic version of Schering Plough’s Clarinex tablets.The company has received the approval for generic Clarinex tablets in the strength of 5mg. The tablets are indicated for allergic rhinitis or allergic inflammation of the nasal airways. Clarinex tablets (5mg) have annual sales of nearly $212 million in the US.
Allergic Rhinitis occurs when an allergen such as pollen or dust is inhaled by an individual with a sensitised immune system and triggers antibody production. In a separate statement, the company said it has received approval from USFDA for generic Tiazac capsules (Annual Sales of $ 12 m) used for treating high blood pressure.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: